At the International Conference on Lymphocyte Engineering (ICLE) 2022, Elvira D’Ippolito, PhD, from the Technical University of Munich, Munich, Germany, describes a session focused on new approaches in lymphocyte engineering. Avidity-controlled chimeric antigen receptors (AvidCARs) are described, which aim to support the development of controllable CAR therapies with improved specificity. In another presentation, cell membrane permeabilization with photothermal nanofibres is highlighted for the potential safe and efficient production of engineered cells for therapeutic applications such as adoptive T cell therapy. Dr D’Ippolito also introduces a novel tumor model for the study of cellular immunotherapy using humanized mice, as well as a study demonstrating the functional CRISPR dissection of gene networks controlling regulatory T (Treg) cell identity. This interview took place at ICLE 2022.

свернуть